Literature DB >> 8631128

Autoregulation of human CYP1A1 gene promotor activity in HepG2 and MCF-7 cells.

E C Jørgensen1, H Autrup.   

Abstract

Cytochrome CYP1A1 gene expression, induced by polycyclic aromatic hydrocarbons and dioxins, eg. 2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD), is regulated mainly at the level of transcription. Inducible activation of the CYP1A1 promotor is mediated by a ligand-dependent transcription factor dimer complex including the aryl hydrocarbon receptor (AHR) and the AHR nuclear translocator (ARNT) proteins. Additional factors seem to be involved in tissue- and cell-specific modification of the induction process. In the present study HepG2 and MCF-7 cell lines were used to examine a possible cell-specific autoregulation of CYP1A1 promotor function. Chimeric CYP1A1-CAT reporter constructs and a human CYP1A1 cDNA expression plasmid were used in transient co-expression experiments. In HepG2 cells co-expression of increasing amounts of CYP1A1 cDNA significantly down-regulated constitutive as well as the TCDD-induced CYP1A1 promotor driven CAT activity. In contrast, co-transfection of MCF-7 cells with a 3-fold molar excess of CYP1A1 cDNA relative to the CYP1A1-CAT reporter construct caused an approximately 2-fold increase in the TCDD-induced CAT activity, whereas no effect was observed on constitutive promotor activity. This autoregulatory mechanism(s) of the human CYP1A1 gene product was independent of specific 5' flanking promotor segments tested. RT-PCR analyses did not indicate any changes in mRNA level of AHR and ARNT in the co-transfection studies. Thus these studies show that the human CYP1A1 gene is exposed to cell-specific autoregulation, probably achieved via different functions of trans-acting factors.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8631128     DOI: 10.1093/carcin/17.3.435

Source DB:  PubMed          Journal:  Carcinogenesis        ISSN: 0143-3334            Impact factor:   4.944


  7 in total

1.  Proteasome inhibition induces nuclear translocation and transcriptional activation of the dioxin receptor in mouse embryo primary fibroblasts in the absence of xenobiotics.

Authors:  B Santiago-Josefat; E Pozo-Guisado; S Mulero-Navarro; P M Fernandez-Salguero
Journal:  Mol Cell Biol       Date:  2001-03       Impact factor: 4.272

2.  An autoregulatory loop controlling CYP1A1 gene expression: role of H(2)O(2) and NFI.

Authors:  Y Morel; N Mermod; R Barouki
Journal:  Mol Cell Biol       Date:  1999-10       Impact factor: 4.272

Review 3.  Repression of gene expression by oxidative stress.

Authors:  Y Morel; R Barouki
Journal:  Biochem J       Date:  1999-09-15       Impact factor: 3.857

4.  Comparison of short-term estrogenicity tests for identification of hormone-disrupting chemicals.

Authors:  H R Andersen; A M Andersson; S F Arnold; H Autrup; M Barfoed; N A Beresford; P Bjerregaard; L B Christiansen; B Gissel; R Hummel; E B Jørgensen; B Korsgaard; R Le Guevel; H Leffers; J McLachlan; A Møller; J B Nielsen; N Olea; A Oles-Karasko; F Pakdel; K L Pedersen; P Perez; N E Skakkeboek; C Sonnenschein; A M Soto
Journal:  Environ Health Perspect       Date:  1999-02       Impact factor: 9.031

5.  Inhibition of E2-induced expression of BRCA1 by persistent organochlorines.

Authors:  Thomas Rattenborg; Irene Gjermandsen; Eva C Bonefeld-Jørgensen
Journal:  Breast Cancer Res       Date:  2002-07-24       Impact factor: 6.466

6.  DNA damage and cell cycle arrest induced by 2-(4-amino-3-methylphenyl)-5-fluorobenzothiazole (5F 203, NSC 703786) is attenuated in aryl hydrocarbon receptor deficient MCF-7 cells.

Authors:  V Trapani; V Patel; C-O Leong; H P Ciolino; G C Yeh; C Hose; J B Trepel; M F G Stevens; E A Sausville; A I Loaiza-Pérez
Journal:  Br J Cancer       Date:  2003-02-24       Impact factor: 7.640

7.  Assessment of Cytokeratin-19 Gene Expression in Peripheral Blood of Breast Cancer Patients and Breast Cancer Cell Lines.

Authors:  Saeideh Keyvani; Nasrin Karimi; Zahra Orafa; Saeid Bouzari; Mana Oloomi
Journal:  Biomark Cancer       Date:  2016-04-28
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.